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sleep and has a wide-ranging impact on quality of life. Valid tools to
measure the patient-reported impact of nocturia are essential for
evaluating the value of treatment, but the available tools are sub-
optimal. Objectives: This study reports the development and valida-
tion of the Nocturia Impact Diary—an augmented form of the
Nocturia Quality of Life questionnaire designed to be completed in
conjunction with the widely used 3-day voiding diary. Methods: The
process comprised three steps: Step 1: Development of a concept pool
using the Nocturia Quality of Life questionnaire and data from
relevant studies; Step 2: Content validity study; Step 3: Psychometric
testing of construct validity, reliability, and sensitivity of the diary in a
randomized, placebo-controlled study in patients with nocturia.
Results: Step 1: Fourteen items and 4 domains were included in the
ﬁrst draft of the diary. Step 2: Twenty-three patients with nocturia
participated in the cognitive debrieﬁng study. Items were adjustedee front matter Copyright & 2014, International S
r Inc. This is an open access article under the CC
ons.org/licenses/by-nc-nd/3.0/).
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openhagen S, Denmark.accordingly, and the content validity was high. Step 3: Fifty-six patients
were randomized to desmopressin orally disintegrating tablet or pla-
cebo. The diary demonstrated high construct validity, with good sensi-
tivity and a good ﬁt to Rasch model, as well as high internal consistency,
discriminatory ability, and acceptable sensitivity to change. Results
indicated that the diary was unidimensional. Conclusions: The Nocturia
Impact Diary is a convenient, validated patient-reported outcome
measure. It should be used in conjunction with a voiding diary to
capture the real-life consequences of nocturia and its treatment.
Keywords: health-related quality of life, nocturia, reliability and
validity, voiding diary.
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Nocturia is deﬁned as waking at night at least once to void [1].
Although ﬂuctuations in severity are common [2], it can be a chronic,
unremitting condition, with patients averaging several voids per
night for many years. Their sleep is therefore subject to persistent,
repeated interruptions, and nocturia has wide-ranging implications
for patients’ quality of life (QOL) [3,4], productivity [5], longer-term
physical and mental health [6,7], and possibly mortality [8].
Several studies have reported the impact of nocturia on patients’
health-related quality of life using recognized measurement tools,
which are generic (e.g., 12-item Short-Form health survey) [7,9], or
symptom-speciﬁc (e.g., Nocturia Quality of Life [N-QoL]) [10,11]. The
N-QoL is the most frequently used symptom-speciﬁc nocturia ques-
tionnaire. It was validated in a study conducted in 2004 involving
onlymales [10], and the content validity (i.e., whether it appropriately
and comprehensively measures the concept of interest) was reex-
amined in a later study [12]. Nevertheless, currently there is no
questionnaire assessing the impact of nocturia on QOL that meets
the Food and Drug Administration’s (FDA’s) 2009 guidelines forvalidity [13], mainly because the recall period (14 days or 1 month)
is considered too long for a ﬂuctuating disease and because the
documentation for content validity is considered incomprehensible.
Valid patient self-reported assessments of disease burden and
beneﬁt of therapy are essential to evaluate the full clinical value of
treatment for the patient. Rather than designing a de novo instrument,
this study used the N-QoL as a basis for developing an enhanced
content-valid tool in close dialogue with the FDA and its Study
Endpoints and Labelling Development team. This tool—the Nocturia
Impact Diary (NI Diary)—is capable of providing direct evidence of
clinical beneﬁt with reduction in the number of nocturnal voids, has a
recall period of one night and day, and is to be completed for three
consecutive days. Thus, it complements the 3-day voiding dairy, which
is guideline-recommended for the assessment of urinary symptoms to
provide a complete evaluation of patients with nocturia [14].
This article outlines the process of development and valida-
tion of the NI Diary (see Appendix A found at http://dx.doi.org/10.
1016/j.jval.2014.06.007), which comprised three main steps: Step
1: Development of a concept pool using the N-QoL questionnaire
and data from relevant studies; Step 2: Content validity study;ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
BY-NC-ND license
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V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 9 6 – 7 0 6 697and Step 3: Psychometric testing of construct validity, reliability,
and sensitivity of the diary in a clinical trial. Besides the FDA
patient-reported outcome guidelines, the NI Diary is consistent
with recent guidelines on appropriate methods of establishing
content validity, published by the International Society for
Pharmacoeconomics and Outcomes Research [15,16] and by the
International Society for Quality of Life Research [17].Methods
Step 1: Development of a Concept Pool
How and why nocturia affects patients’ daily living has been
explored in several qualitative studies. To ensure that the NIImpact due 
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Fig. 1 – Summary of detailed origin of NI draft diary instrument d
diary draft and the themed speciﬁc impacts based on concept elic
(Piedmont study ¼ blue and Atlanta study ¼ red). Themed speciﬁ
unpublished material. NI, Nocturia Impact.Diary reﬂects important aspects of nocturia experienced by
patients, a comprehensive pool of concepts was compiled from
the literature: a review of several nocturia content validity
studies [12] and an original content validity study [18]. The
conceptual framework of the NI Diary (Fig. 1) summarizes areas
of nocturia impact derived from the content validity studies and
shows the overall phrasing of items/questions and domains.
Step 2: Cognitive Debrieﬁng Study Conﬁrming Selected Item
Pool
A qualitative cognitive debrieﬁng study was performed to
evaluate the content validity and comprehensiveness of
the item pool. Patients were asked to participate in one of
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ed during day
y next day
antity and quality of sleep
 low energy levels
ce of sleep loss on one's mood
ep
eturning to sleep
tigued next day and consequences of this
oncentrating the next day
ctive next day
 treatment is effective
t condition will worsen in future
d about getting up at night
bility to concentrate and forgetfulness
rry out responsibilities
ut future
inking of nocturia
e's beliefs about oneself
 burden and loss of control
ntrol
ns ineffective
of getting older
ipation in enjoyable activities
bout disturbing others in house
out how much is drunk
elationships
tyle changes
 physical lifestyle, eg fluid intake, 
bits and sleep location
f injuries
ut bother to others
ffect on social life
l interventions
minor problem
e of condition
 fluids
rference with daily life
omains. Step 2. List of the connection between domains in NI
itation studies by Abraham et al. [10] ¼ green, Mock et al. [12]
c items in bold if mentioned in Booth et al. [18] and/or Ferring
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 9 6 – 7 0 6698interviews were conducted and transcribed by a professional
interviewer.
Patients were recruited from two US placebo-controlled
randomized controlled trials evaluating desmopressin orally
disintegrating tablet (ODT; NCT01223937, NCT01262456) [19,20].
Patients were either completers or dropouts, who ﬁnished the
study 30 or more days before inclusion in the debrieﬁng study.
Inclusion criteria for the trials included two or more voids for
three consecutive nights during screening, no major psycholog-
ical problems or known alcohol/substance abuse, no work/life-
style factors interfering with nighttime sleep, no obstructive
sleep apnea or uncontrolled sleep disorders, no evidence of
severe daytime voiding dysfunction, and written informed con-
sent. The study was completed according to the Declaration of
Helsinki and approved by institutional review boards.
The focus group meetings comprised four parts, in which
patients were asked to 1) discuss the meaning and relevance of
each question; 2) assess whether the diary adequately covers all
aspects of nocturia and its related complaints (comprehensiveness);
3) evaluate the clarity of instructions and response options (e.g.,
terminology, phrasing, and format); and 4) complete the diary
individually. Because this process was seeking to reﬁne an existing
instrument (i.e., N-QoL) rather than create a new one, patients were
encouraged to suggest other areas of interest (item elicitation) to
ensure that the NI Diary covered all important topics after they had
discussed the relevance and importance of the draft questionnaire.
Transcripts of the cognitive debrieﬁng were analyzed and items
adjusted as appropriate in response to feedback generated by the
sessions. A revised draft (version 2) was developed on the basis of
responses to each of these phases. Based on advice from the SEALD
team, two items exploring subpopulations were reintroduced and a
Rasch analysis was conducted on the preliminary, cross-sectional
data to conﬁrm the changes into a slightly modiﬁed version 3.
Step 3: Psychometric Testing of Construct Validity, Reliability,
and Sensitivity: IMPACT Study
Version 3 of the NI Diary was subjected to formal psychometric
testing in a double-blind, placebo-controlled, randomized, ﬁxed-
dose study of desmopressin ODT (NCT01552343- denoted IMPACT
Study). Patients with nocturia were recruited from the random-
ized controlled trials used in step 2 [19,20].
Patients included in the IMPACT study were responders on
desmopressin (reduction Z33% in nocturnal voids after 1 month)
or nonresponders on placebo (o33% reduction). A greater degree of
variation in these parameters ensures a more adequate test of theFig. 2 – Study design of the IMPACT study (psychometric testing
n ¼ 5; o2 voids/night during screening: n ¼ 4; uncontrolled diab
Nocturia Impact.correlation with objective urology end points and therefore chosen to
ensure the inclusion of a broadly representative patient population.
The main objectives of this study were to assess the reliability
and validity of the diary, the association between reduction in the
number of nocturnal voids and mean changes in diary scores
(indicating the sensitivity of the total score), and which items
accounted for the main difference in the change in total NI score
in the treatment versus placebo groups.
Figure 2 shows the study design of the IMPACT study. Part 1
was composed of a screening period, initiated with a screening
visit (visit 1) at 20 to 28 days before visit 2 (baseline). During part
1, no investigational product was given. The voiding and NI
diaries were completed immediately after visit 1 (the “screening
diary”), and again completed during the week before visit 2 (the
“baseline diary”). These diaries were separated by a minimum
14-day period and completed on the same days of the week,
over three consecutive days. The NI diaries were to be com-
pleted without inﬂuence from family or friends, and the inves-
tigator explained that there were no “right” or “wrong” answers.
The voiding diaries did not include the ﬁrst morning void as a
nocturnal void, and the time to ﬁrst void was deﬁned as the
time from going to bed with the intention of sleeping until the
ﬁrst nocturnal void (or until waking in the morning if there was
no nocturnal void). Patients were instructed to empty their
bladder before bed and to drink to satisfy thirst only.
Part 2 was the treatment period. Females were randomized to 25
mg desmopressin ODT or placebo and males to 75 mg desmopressin
ODT or placebo. Randomization was stratiﬁed because of the
gender-speciﬁc dosing of Nocdurna using preplanned computer-
generated randomization lists. Treatment was initiated in the
evening of visit 2 and subsequently taken nightly for 1 month.
During the treatment period, one NI Diary and one voiding diary
were completed just before the end-of-trial visit (day 29  3).
Statistical Methods (IMPACT Study)
The ﬁnal NI Diary is a 12-item questionnaire. Responses are
scored from 0 (lowest impact) to 4 (highest impact). Item 12 is a
rating of overall impact, and the total score is derived by
summing the scores from the core items 1 to 11 (Q1–Q11). The
overall impact (Q12) and NI total scores were analyzed on the
basis of a standardized scale from 0 to 100 (lowest impact–greatest
impact), with raw scores standardized as follows:
Transformed score ¼ Sum of component items score 100
Maximum possible raw score). *Reasons for screening failure: signs of renal impairment:
etes mellitus: n ¼ 1; other: n ¼ 1. EOT, end of treatment; NI,
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must be completed for the diary to be included in analyses.
Values were averaged over the 3-day period and included in
the diary.
A sample of n ¼ 52 was required for 80% power to detect a
correlation of r ¼ 0.4 between change from baseline to month 1 in
nocturnal voids and change in total NI score (α ¼ 0.05, two sided).
The study was not powered to show superior efﬁcacy of desmo-
pressin versus placebo.
The psychometric analyses to establish construct validity,
reliability, and sensitivity were prospectively deﬁned and all
validation end points were tested using both classic item
response theory and Rasch analysis to ensure the best possible
level of validation evidence.Results
Step 1: Development of a Concept Pool
As a result of a guidance meeting with the FDA, a comprehen-
sive list of impacts was developed (Fig. 1). This list was based
on the thematic overview from Mock et al. [12], which compiled
data from three nocturia content elicitation studies. Mock
et al. [12] qualitatively analyzed patient transcripts collated by
two research groups (Atlanta and Piedmont) using semi-
structured interviews and focus groups. From the Atlanta site
transcripts, 48 items and 13 thematic areas were derived; the
Piedmont site reported 64 items and 12 thematic areas. Two
themes identiﬁed by these groups were not present in the
original N-QoL: “fear of falling at night” and “nocturia makes
me feels old.”
To complete the impact list for this study, data from Booth
et al. were included along with data from an unpublished
cognitive debrieﬁng study to document the content validity of
the N-QoL conducted by Ferring and involving ﬁve women [18].
Booth et al. isolated four important key characteristics/domains
of nocturia: debilitating, frustrating, distressing, and puzzling.
The data are presented in a very raw format under these four key
headings. This demonstrates overall operability but without
identifying speciﬁc thematic areas. Thus, this second article
was used directly to feed the overall domain list, but its lack of
speciﬁc thematic areas meant that it could have been used only
as supporting evidence for the thematic areas of the overall
domains (see step 2).
Based on the speciﬁc impact list and the additional inspiration
from Booth et al. [18] and Ferring’s unpublished content validity
study, 14 draft NI Diary items were included in version 1,
comprising four domains. Items compiled in step 1 were
rephrased to be contained within a diary relating to the previous
night and/or day. Possible responses were made appropriate for
daily diary use: “not at all” (0), “slightly” (1), “moderately” (2),
“quite a bit” (3), and “a great deal” (4). The ﬁnal conceptual model
of the NI draft diary is presented in step 4.Table 1 – Cognitive debrieﬁng subject demographic char
Characteristic Men
N 11
Age o65 years (%) 5 (45)
Age Z65 years (%) 6 (55)
Mean age (y) (range) 58 (37–88)
Number of voids per night at baseline Z2
* One patient left the interview because of time constraint.Step 2: Cognitive Debrieﬁng Study
Twenty-three adults with nocturia participated in focus groups
stratiﬁed by age and sex (Table 1): men younger than 65 years
(n ¼ 5) or 65 years or older (n ¼ 6) and women younger than 65
years (n ¼ 7) or 65 years or older (n ¼ 5). The item tracking sheet
(Table 2) summarizes feedback on comprehensiveness, rele-
vance and importance, and the response distribution for each
item. Any changes made to the items (for inclusion in version 2),
and a number of additional changes based on Rasch analysis
and the transcripts from the focus groups, were incorporated
into version 3 and are noted in Table 2 with the rationale for
changes. The additional alterations were primarily based on the
cognitive debrieﬁng study but were further tested with the
Rasch analysis.
Patients rated the wording and design of the NI Diary as
generally acceptable and straightforward. Based on overall feed-
back, however, an explanation of the meaning of nocturia and a
general introduction were included for future versions.Step 3: Psychometric Testing: IMPACT Study
Of the 67 patients initially screened, 56 were randomized and
included in the study—29 to placebo and 27 to desmopressin ODT
(Fig. 2). All 56 randomized patients completed the study. Patient
characteristics are listed in Table 3.
See Table 4 for an example of the two-way statistical testing
and Table 5 for an overview of the psychometric tests performed,
results, and interpretation.
Rasch analysis was possible to use because of the unidi-
mentionality assumption (Table 4). This was highly supported
by the factor analysis, which indicated that the diary was
unidimensional at all time points (Fig. 3). There were no
signiﬁcant differences between items that accounted for the
main differences in the change in total NI score between study
groups.
The NI Diary demonstrated a high degree of construct validity,
with good sensitivity and stability in Rasch analysis. “Known
group” assessment also demonstrated a strong ability to distin-
guish between patients with varying nocturia severity. The diary
had high internal consistency, as shown by Cronbach’s alpha and
individual item–total score correlations. Sensitivity to change
was supported by Pearson and partial correlations; although the
correlation was relatively low, it was signiﬁcant (P ¼ .018) with a
large Cohen’s D effect size.
Following psychometric testing, a minor change was made to
item 8 (Version 4: “Were you worried about tripping or falling?”)
to avoid the misinterpretation that the question relates to falling
asleep. This was picked up in the focus groups and also was
raised as an issue by translators. Item 12 was also modiﬁed for
the ﬁnal version of the diary (Version 4: “Overall, to what extent
does nocturia presently impact your life?”) to ensure that the
item assessed the daily impact of nocturia.
Establishing the point change that represents a clinically
relevant difference on the NI Diary in only 56 patients isacteristics.
Women All
13 24*
7 (54) 12 (50)
6 (46) 12 (50)
61 (40–80) 61 (37–88)
Z2 Z2
Table 2 – Item tracking sheet detailing patient feedback, response distributions, any changes made between V1 and V4 of the diary, and the rationale
for these changes.
NI Diary draft
item (V1)
Ease of understandability,
relevance, and patient
quotations
Important* Response variation Change to item* Rationale for change Final item (V4)
Thinking over the day, to what extent
(1)… was it difﬁcult
to concentrate?
Easy to understand 21/23 Highly skewed. Only
use of ﬁrst three
options.
None. No change based on high
importance and
relevance. Some concern
about lack of response
variation.
(1) … was it difﬁcult to
concentrate?Fþ65: “I think it’s clear. It’s
understandable.”
Relevant without alterations
F-65: “If you don’t get enough
sleep, you are tired and cranky.
The next day it’s hard to focus
on what you’re doing
sometimes.”
(2) … did you feel
low in energy?
Easy to understand 21/23 Skewed. Use of ﬁrst
four options.
Merged with Q3. Merged with Q3 because of
redundancy. Important
to mention “tired”
because this seems to
increase response
variation.
(2) … did you feel low in
energy and/or tired?F-65: “You can understand. It’s to
the point.”
Questions 2 and 3 redundant.
Combine into one.
M-65: “Probably (not important)
because of the two questions. If
there was only one of them
there, then I might change it to
very important.”
(3) … did you feel
tired?
Easy to understand 21/23 Less skewed than Q2.
Use of ﬁrst four
options.
Merged with Q2. Merged with Q2 because of
redundancy.
None.
F-65: “It’s easy.”
See Q2
F-65: “If I’m low in energy, I’m
tired. You’ve reworded the
question.”
(4) … were you
unable to be
productive?
Easy to understand 19/23 Skewed. Use of ﬁrst
four options.
Question
speciﬁed by
mentioning work
and personal
activities.
Question not modiﬁed to
focus on positive version,
as negative phrasing
related to direction of
scale. Question was
speciﬁed by including
“work” and “personal
activities.” Not divided
into two questions to
avoid missing data from
all not professionally
employed patients.
(3)… were you unable to
be productive at work
or complete your
personal, daily
activities?
F-65: “It’s pretty straightforward.”
Seems more natural to ask in a
more positive light. Could be
asked speciﬁcally about being
productive at work vs.
productive at home or in
personal activities.
M-65: “Or maybe instead of, ‘Were
you unable to be productive?’
you can put, ‘Were you able to
be productive?’ ”
continued on next page
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(5) … did you avoid
participating in
activities that
you enjoy
because of
nocturia?
Easy to understand 19/23 Skewed, but fully
distributed.
None. Questions not rephrased to
avoid suggesting
activities that are
relevant only for some.
Even without specifying
the activities, the
question seems to be
understandable,
important, and shows
scoring variability.
(4) … did you avoid
participating in
activities that you
enjoy?
Mþ65: “I think it’s easy to
understand because really what
happens at night doesn’t really
affect my daytime very much at
all.”
Relevant without alterations,
though could differentiate
between types of activities.
M-65: “With [question] ﬁve it’s
participating in activities. Does
that mean after work and
productive at work? Maybe you
could specify four and ﬁve to
which they are talking about.”
(6) … did you feel
irritable or
moody during
the day today?
Easy to understand. 11/23 Very skewed. Very
relevant for one
patient.
V2: Delete. V2: The question is not
rated relevant for half of
the patients.
Furthermore, the scoring
is highly skewed.
(5) … did you feel
irritable or moody?Fþ65: “I understood. Some people
do get moody because they
didn’t get enough sleep.”
V3: Reinserted. V3: FDA comment.
(7) … did you limit
your ﬂuid intake?
Easy to understand. 23/23 Little skewed, all
options used.
None. Question not rephrased
because it was rated
important, relevant, and
understandable with
diverse scoring.
(6) … did you limit your
ﬂuid intake?Fþ65: “In the context of going into
a study on nocturia, yes. It’s
quite easy.”
(8) … are you
preoccupied that
nighttime
voiding is a sign
of getting older?
Easy to understand. 11/23 Little skewed, but all
response options
used.
V2: Rephrase. V2: Because of the lack of
importance for many
patients (even though the
responses are very
acceptably distributed),
the question was
rephrased as suggested
to “concern.”
None.
F-65: “It’s clear.”
V3: Delete. V3: FDA comment:
endorsement due to age
or nocturia?
Use of the word “preoccupied”
seems too strong, may be more
of a “concern” than a continual
preoccupation.
Mþ65: “If you’re preoccupied with
something, you’re thinking
about this all the time.”
Thinking about last night, to what extent …
(9) … did you lay
awake without
being able to
return to sleep?
Easy to understand. 19/23 Very nicely distributed. Rephrasing. The question is important
and relevant and the
scoring works. Small
adjustment to clarify.
Change of “lay” to “lie.”
(7) … did you lie awake
without being able to
return to sleep after
getting up to use the
bathroom at night?
F-65: “No, I think it’s pretty self-
explanatory.”
Adding a reference to “after getting
up to use the bathroom at night”
might make the question more
clear.
Mþ65: “Something in there needs
to tie it to the fact that you got
up because you had to void.”
continued on next page
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Table 2 – continued
NI Diary draft
item (V1)
Ease of understandability,
relevance, and patient
quotations
Important* Response variation Change to item* Rationale for change Final item (V4)
(10) … did you feel
you got too little
sleep?
Easy to understand. 21/23 Very nicely distributed. None (order
swapped with
following
question).
Patients suggested a change
so question rephrased
positively “Did you feel
you got enough sleep?”
but cannot be done
because of response
direction.
(9) … did you feel you
got too little sleep?Fþ65: “It’s easy to understand.”
Could be rephrased to say “Did you
feel you got enough sleep?”
F-65: “I would say, ‘do you feel you
got enough sleep?’ Instead of,
‘do you feel you got too little
sleep?’”
(11) … were you
worried about
falling?
Difﬁcult to understand 5/23 Highly skewed. V2: Delete. V2: The question was
deemed relevant only by
a small group of patients.
But these patients found
it highly important.
Deleted.
(8) … were you worried
about tripping or
falling?
F-65: “I don’t understand it. I don’t
know what it has to do with
anything.”
V3: Reinsert (and
swap order with
preceding
question).
V3: Question kept in diary
to include assessment of
a huge problem for a
small group of patients.
Specify “falling when getting up at
night to use the bathroom”;
many respondents could not
relate to this question because it
was not a concern at all.
V4: Addition of “tripping” to
avoid misinterpretation
of “falling” as “falling
asleep.”
Mþ65: “Falling when you had to
get up to go to the bathroom.”
(12) … were you
worried that you
would wake up
people in the
house?
Easy to understand. 12/23 Highly skewed and
ceiling effect in
previous Ferring
RCT (NCT00477490).
Deleted. Question deleted because
only half of the patients
found it important and
responses were highly
skewed in several
studies. Relates only to a
subgroup of patients,
creating missing data
from all single-living
patients.
None.
Fþ65: “Very easy to understand.”
Relevant without alterations.
Fþ65: “If there are more people
living in the house, you know, if
you’re in the house with four or
ﬁve other people, it would be
very important.”
Overall, to what extent …
(13)… do you worry
that the nocturia
will get worse in
the future?
Easy to understand. 20/23 Nicely distributed. None. Question is important,
relevant, easy to
understand, and scoring
is nicely distributed.
(10)… do you worry that
the nocturia will get
worse in the future?
M-65: “The question is ﬁne.”
Suggested by patients in the
cognitive debrieﬁng
study.
(11) … are you
concerned with
where the bathroom
is when away from
home overnight?
Relevant without alterations.
Mþ65: “It’s very important to me
because if it gets any worse, I
won’t have to go to bed at all.”
continued on next page
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Table 3 – Patients’ characteristics at baseline
(IMPACT study).
Characteristic Placebo Desmopressin
Women 14 (48) 12 (44)
Men 15 (52) 15 (56)
Age (y)
Mean  SD 63.9  12.5 63.6  11.2
Minimum, maximum 39, 86 40, 85
Age (y), n (%)
o65 11 (38) 13 (48)
Z65 18 (62) 14 (52)
Race, n (%)
White 25 (86) 23 (85)
Black/African American 4 (14) 2 (7)
Asian 0 1 (4)
American Indian/Alaska
native 0 1 (4)
BMI (kg/m2)
Mean  SD 32  5.98 27.4  4.74
Minimum, maximum 23.7, 43.2 18.1, 35.1
Number of nocturnal voids
Mean  SD 2.7  0.68 3.2  1.05
Minimum, maximum 2, 4.7 2, 5.7
Mean time to ﬁrst nocturnal
Void (min)
Mean  SD 153  50.7 140  32
Minimum, maximum 85, 270 84.3, 230
BMI, body mass index.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 9 6 – 7 0 6 703challenging and further studies are needed to continue the
iterative nature of a questionnaire development process.
A meaningful clinical difference, based on the responder analysis
and Cohen’s D calculation, however, was estimated to beTable 4 – Two-way psychometric testing on con-
struct validity where the Rasch PSI test is supported
by the use of classic response theory (known as
groups’ validity).*
Time PSI score (95% CI) Fit to the
Rasch model
χ2 (P)
Baseline, day 2 0.898 (0.844–0.934) 29.8 (0.124)
Baseline, day 3 0.906 (0.856–0.940) 31.1 (0.095)
Baseline, day 4 0.911 (0.864–0.943) 47.8 (0.001)
Month 1, day 2 0.876 (0.81–0.919) 17.3 (0.749)
Month 1, day 3 0.860 (0.787–0.909) 33.9 (0.050)
Month 1, day 4 0.853 (0.778–0.905) 31.4 (0.088)
Difference in NI total score
between known groups
(o3 vs. Z3 voids)
95% CI and P
value
Baseline (total
NI Diary
score)
13.6 (26.0 to 1.2); P
¼ 0.032
Note. Degrees of freedom ¼ 22 for all days.
CI, conﬁdence interval; NI, Nocturia Impact; PSI, person
separation index.
* Both statistical analyses support a strong construct validity of
the NI diary. Rasch P values o0.05 indicate that
unidimentionality cannot be rejected.
Table 5 – Summary of psychometric testing and results.
Tool used Reason Data* Clinical relevance
Rasch analysis Stability over time Data are within
conﬁdence interval
Highly supportive when
within conﬁdence interval
ICC Item redundancy Baseline: r ¼ 0.91 Highly supportive when r ¼
0.75–1.0 [25]
Factor analysis Number of domains One dimension. 0.85–0.96 Highly supportive if 40.6,
supportive if 40.4 [26]
Rasch analysis Number of domains Borderline signiﬁcant A prerequisite for use of
Rasch
Cronbach’s α for NI summary score Item redundancy α ¼ 0.94 Highly supportive if between
0.75 and 0.83 [27]
Items total correlation Item redundancy r ¼ 0.465, P o 0.001 Highly supportive if40.3 [28]
Data from the cognitive debrieﬁng study Content validity High Documented in Table 4
Known group validity (o3 voids vs. Z3 voids) Severe vs. not
severe nocturia
NI total: Diff. 13.6 at
baseline
P ¼ 0.0318
Rasch analysis (separation reliability)—Person
separation index
Logical relationship
overall model
0.9 at baseline Highly supportive if 40.70
Fit to Rasch model Logical relationship
overall model
At baseline two of three
values are P 4 0.05
Highly supportive if all
values of P 4 0.05
Pearson correlation coefﬁcient between nocturia
reduction and total score improvement
Correlation Correlation r ¼ 0.31 P ¼ 0.018
Responder analysis (33%)/Cohen’s D Ability to detect
difference
Cohen’s D: 0.73 Highly supportive if 4 0.5
[29]
ANCOVA Efﬁcacy Effect: 0.4 P ¼ 0.064
Floor and ceiling effect Not too skewed Supportive
Acceptability: % of missing data None Highly supportive
ANVOVA, analysis of covariance; ICC, intraclass correlation coefﬁcient.
* Full analysis set was used; where data were available at three time points, results for baseline are shown.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 9 6 – 7 0 67047.3 points. The cross-sectional split between severe and less
severe nocturia at study start showed a relevant clinical differ-
ence of 8.6 to 13.6 points. Based on the data currently available,
our educated guess is that a clinical difference on the NI Diary is
obtained with a difference of between 7 and 10 points in diary
scores. This is further supported by a recent real-life cross-
sectional survey [21] in which a reduction of one void (going
from four to three, three to two, and two to one voids per night)
generated changes in the NI Diary total score in the range of 7 to
10 points. A minimal clinically important difference of 5 points isFig. 3 – Factor analysis of number of domains in NI Diary. Scree
the NI Diary has one dominant dimension. The sharp drop in th
data is accounted for by only one factor. NI, Nocturia Impact.suggested, whereas a difference of 10 points denotes a highly
clinically important difference. More trials are required to explore
this further and establish a proper minimal clinically important
difference.Discussion
Nocturia is a prevalent condition worldwide [22], with a negative
impact on patients’ overall health and QOL, likely due to chronicplots of the principal-component analysis clearly show that
e plot provides evidence that the bulk of the variation in the
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 9 6 – 7 0 6 705sleep interruptions [7,23,24]. Tools to measure its impact and
potential beneﬁts of treatment, however, have hitherto been
suboptimal.
The NI Diary is a 12-item, unidimensional 3-day diary of the
impact burden associated with nocturia. Its recall period is
identical to that of the 3-day voiding diaries. The NI Diary
has undergone a rigorous development and testing process and
was developed in dialogue with the FDA and in line with
International Society for Pharmacoeconomics and Outcomes
Research and the International Society for Quality of Life
Research guidelines [16,17]. The diary evolved from the N-QoL
questionnaire [10] and additional published content validity
studies [12,18]. The content validity was further strengthened in
several cognitive debrieﬁng and item elicitation focus group
interviews.
Psychometric testing conﬁrmed that the NI Diary has high
construct validity, is unidimensional, is stable over time, and has
high internal consistency and minimal item redundancy. The
diary is sensitive to treatment effects or changes over time, with
Cohen’s D providing initial support for treatment sensitivity. The
Pearson correlation between reduction in nocturnal voids and NI
total score was numerically relatively low but statistically sig-
niﬁcant—the IMPACT trial could not be powered to demonstrate
sensitivity fully; thus, additional larger studies are required as
part of the iterative process that constitutes a questionnaire
development process. The NI Diary showed adequate variance
on most items, with a slight ﬂoor effect. The latter may cause
difﬁculties in demonstrating a positive treatment effect in studies
of therapy, though the signiﬁcant Pearson correlation indicates
that an association between improvement in symptoms and
decreased burden was detected.
The NI Diary is available as a fully validated patient-reported
outcome measure allowing clinicians and researchers to quantify
the impact of nocturia on patients. It is simple, quick to complete,
and available in several languages (US [English, Spanish], UK
English, Spanish, French, German, Japanese). It is recommended
that the NI Diary be used with the 3-day voiding diary to clarify
the impact of nocturnal voiding on each individual patient and to
monitor the effects of treatment. A more complete assessment of
the patient’s QOL, the burden imposed by nocturia, and improve-
ments achieved by clinical management can thereby be gained.Conclusions
The NI Diary has high content validity, construct validity, and
reliability. Cohen’s D analysis indicates adequate treatment
sensitivity, although further studies in larger samples are
required to conﬁrm the diary’s responsiveness to nocturia
treatment. The NI Diary is the ﬁrst nocturia impact assessment
tool developed in close dialogue with the FDA and in accord-
ance with the new FDA patient-reported outcome validation
guidelines. Therefore, it represents a clinically meaningful
measurement tool that should be used in conjunction with
the voiding diary in cross-sectional assessments of patient
burden and in assessments of changes with nocturia
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